RegeneRx Biopharmaceuticals, Inc.
RGRX
$0.0002
$0.000.00%
OTC PK
| 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 19.20K | 19.20K | 19.20K | 19.20K | 19.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.20K | 19.20K | 19.20K | 19.20K | 19.20K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 19.20K | 19.20K | 19.20K | 19.20K | 19.20K |
| SG&A Expenses | 324.10K | 328.00K | 303.70K | 484.00K | 363.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 324.10K | 328.00K | 303.70K | 484.00K | 363.00K |
| Operating Income | -304.90K | -308.80K | -284.50K | -464.80K | -343.80K |
| Income Before Tax | -385.20K | -390.90K | -366.50K | -546.00K | -424.10K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -385.20K | -390.90K | -366.50K | -546.00K | -424.10K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -385.20K | -390.90K | -366.50K | -546.00K | -424.10K |
| EBIT | -304.90K | -308.80K | -284.50K | -464.80K | -343.80K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.27 | -0.27 | -0.26 | -0.38 | -0.30 |
| Normalized Basic EPS | -0.17 | -0.17 | -0.16 | -0.24 | -0.18 |
| EPS Diluted | -0.27 | -0.26 | -0.26 | -0.38 | -0.30 |
| Normalized Diluted EPS | -0.17 | -0.17 | -0.16 | -0.24 | -0.18 |
| Average Basic Shares Outstanding | 1.44M | 1.44M | 1.44M | 1.44M | 1.44M |
| Average Diluted Shares Outstanding | 1.44M | 1.44M | 1.44M | 1.44M | 1.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |